Researchers unveiled ErbB-OSV, an engineered vesicular stomatitis virus (VSV) variant designed to selectively kill metastatic ovarian cancer cells while sparing normal tissue. The study reports a safety profile and potency that compares favorably with the historically used VSV-ON-ΔM51 strain. The therapeutic premise is based on rewired signaling that helps the virus preferentially target tumor cells associated with an ErbB signature, aiming to reduce collateral damage during treatment. For oncology developers, oncolytic viruses remain a major focus where delivery, selectivity, and immune activation all determine translation. If the findings hold up in later preclinical work, engineered targeting may widen the usable population for oncolytic viral approaches in metastatic settings where efficacy has been difficult to sustain.